Finally, with more aggressive chemotherapy regimens such as Taxotere® + Adriamycin® + cyclophosphamide (TAC), grade 3 or 4 neutropenia still occurs in > 90% of patients, despite G-CSF prophylactic therapy [8]. This evidence concerns the gene CSF3 and Decreased total neutrophil count.